Pharmacology · Antifungal Agents

Antifungal Drug Interactions and Therapeutic Drug Monitoring

CYP inhibition profiles, high-priority interaction pairs, calcineurin inhibitor management, and TDM targets

Azole antifungals are the most clinically important inhibitors of CYP2C9 and CYP3A4 in infectious disease practice — fluconazole's dominant action is on CYP2C9 while itraconazole and posaconazole act primarily on CYP3A4; voriconazole potently inhibits all three major CYPs and carries the broadest interaction profile in the class.
Interactions cannot be generalized across the azole class — an interaction proven with voriconazole does not necessarily apply to isavuconazole, and vice versa; each azole has a distinct enzyme inhibition pattern that must be looked up for the specific agent prescribed.
Tacrolimus is the highest-priority calcineurin inhibitor to manage when starting an azole — its narrow therapeutic index and >99% CYP3A4 metabolism mean that azole co-administration without proactive dose reduction risks severe calcineurin inhibitor toxicity including nephrotoxicity and neurotoxicity.
Voriconazole and sirolimus (rapamycin) are contraindicated together — sirolimus AUC increases 500–1000% because sirolimus is almost entirely CYP3A4-metabolized; no dose reduction is safely predictable and the combination should never be used.
TDM is not optional for voriconazole and should be routine for itraconazole oral suspension and posaconazole oral suspension — the sub-therapeutic ranges are associated with treatment failure, while supratherapeutic voriconazole levels cause neurotoxicity and hepatotoxicity.

Abbreviations: CYP = cytochrome P450 · P-gp = P-glycoprotein · TDM = therapeutic drug monitoring · INR = international normalized ratio · AUC = area under the concentration-time curve · mTOR = mammalian target of rapamycin

CYP Inhibition Profiles by Azole

Azole	CYP2C9	CYP2C19	CYP3A4	P-gp
Fluconazole	Potent	Moderate	Moderate	Minimal
Itraconazole	Minimal	Minimal	Potent	Potent
Voriconazole	Potent	Potent	Potent	Moderate
Posaconazole	Minimal	Minimal	Potent	Moderate
Isavuconazole	Minimal	Minimal	Moderate	Moderate

High-Priority Interaction Pairs

Contraindicated

Never Co-Administer

Rifampin + any azole — induces CYP3A4 and P-gp → reduces azole levels to sub-therapeutic; therapeutic failure certain
St. John's wort + any azole — same CYP3A4/P-gp induction mechanism; ask about supplements
Sirolimus + voriconazole — sirolimus AUC increases 500–1000%; no safe dose reduction possible
Sirolimus + posaconazole — same magnitude of interaction; equally contraindicated
Simvastatin or lovastatin + itraconazole — CYP3A4 inhibition → rhabdomyolysis; switch to pravastatin or rosuvastatin

Requires Proactive Management

Act Before Starting Azole

Tacrolimus + any azole — reduce tacrolimus dose before first azole dose; check trough daily for 7 days
Cyclosporine + any azole — reduce dose; monitor levels daily for first week
Warfarin + fluconazole or voriconazole — CYP2C9 inhibition → ↑ INR; check INR at 3–5 days and adjust dose
Sirolimus + isavuconazole — reduce sirolimus to 20–40% of current dose; monitor sirolimus trough
When azole stopped — calcineurin inhibitor levels fall as CYP3A4 inhibition lifts; increase dose prospectively, do not wait for low level

Tacrolimus Dose Adjustment When Starting an Azole

Azole Started	Reduce Tacrolimus To	Monitoring
Voriconazole or Posaconazole	~One-third of current dose	Daily trough days 1–7; adjust to target
Fluconazole	~One-half of current dose	Daily trough days 1–7; adjust to target
Isavuconazole	~Two-thirds of current dose	Daily trough days 1–7; adjust to target
Azole stopped	Increase dose prospectively	Daily trough for 5–7 days until stable

Antifungal TDM Targets

Voriconazole

Trough 1.0–5.5 mg/L

Obtain at Day 5–7 after reaching steady state
Below 1.0 mg/L → treatment failure risk; increase dose
Above 5.5 mg/L → neurotoxicity, hepatotoxicity; reduce dose
Repeat after any dose change, new interacting drug, or CYP2C19 polymorphism concern

Posaconazole

Trough above 0.7 or 1.0 mg/L

Prophylaxis target: above 0.7 mg/L
Treatment target: above 1.0 mg/L (some guidelines: 1.25–1.5)
Most critical with oral suspension — absorption highly variable; DR tablet more reliable
Obtain at Day 5–7

Itraconazole

Trough above 0.5 or 1.0 mcg/mL

Prophylaxis target: above 0.5 mcg/mL
Treatment target: above 1.0 mcg/mL
Obtain at Day 14 — itraconazole reaches steady state more slowly
Toxic range above 10 mcg/mL — peripheral neuropathy, hepatotoxicity

Key Rule — Never Generalize Interactions Across the Azole Class

Each azole has a distinct CYP inhibition fingerprint. Fluconazole's primary action is on CYP2C9 — it raises warfarin and phenytoin levels substantially, but is a weaker CYP3A4 inhibitor than itraconazole or voriconazole. Itraconazole and posaconazole barely touch CYP2C9 but are potent CYP3A4 inhibitors with significant P-glycoprotein inhibition. Voriconazole inhibits all three CYPs potently. Isavuconazole has the mildest inhibition profile and no QTc-prolongation effect.

The most common prescribing error is managing interactions based on class generalizations rather than agent-specific data — for example, assuming that a drug interaction documented with voriconazole applies to isavuconazole, or that a pair safe with fluconazole is safe with posaconazole. Always look up interactions for the specific azole being prescribed. In transplant patients on tacrolimus, the prescriber must proactively reduce the calcineurin inhibitor dose before the first azole dose — waiting for the level to rise and then reacting doubles the risk of toxic exposure.

Suggested References

Author / Source	Title	Publication
Katzung BG, ed.	Basic and Clinical Pharmacology, 15th ed. — Chapter 48: Antifungal Agents	McGraw-Hill, 2021
Brunton LL, Knollmann BC, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed. — Chapter 57: Antifungal Agents	McGraw-Hill, 2023
Venkatakrishnan K, von Moltke LL, Greenblatt DJ	Effects of the antifungal agents on oxidative drug metabolism: clinical relevance	Clin Pharmacokinet. 2000;38(2):111–180
Gubbins PO, Amsden JR	Drug-drug interactions of antifungal agents and implications for patient care	Expert Opin Pharmacother. 2005;6(13):2231–2243
Dodds Ashley ES, Lewis R, Lewis JS, Martin C, Andes D	Pharmacology of systemic antifungal agents	Clin Infect Dis. 2006;43(Suppl 1):S28–S39
Saad AH, DePestel DD, Carver PL	Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants	Pharmacotherapy. 2006;26(12):1730–1744
Dodds-Ashley E	Management of drug and food interactions with azole antifungal agents in transplant recipients	Pharmacotherapy. 2010;30(8):842–854
Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ	Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring	Antimicrob Agents Chemother. 2012;56(9):4793–4799
Pasqualotto AC, Shah M, Wynn R, Denning DW	Voriconazole plasma monitoring	Arch Dis Child. 2008;93(7):578–581
Andes D, Pascual A, Marchetti O	Antifungal therapeutic drug monitoring: established and emerging indications	Antimicrob Agents Chemother. 2009;53(1):24–34
Bruggemann RJ, Alffenaar JW, Blijlevens NM, et al.	Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents	Clin Infect Dis. 2009;48(10):1441–1458
Pappas PG, Kauffman CA, Andes DR, et al.	Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America	Clin Infect Dis. 2016;62(4):e1–e50